Uncategorized

Gamida Cell Ltd. announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants to purchase its ordinary shares.

Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated April 14, 2022, indicating that Biophytis has regained compliance with he Nasdaq Global Select Market minimum bid price requirement.

Everest Medicines announced that it has signed a Memorandum of Understanding for a strategic partnership with a subsidiary of Shanghai Pharma, SPH Keyuan Xinhua Pharmaceutical Co., Ltd.

Agilis Robotics, an innovative spin-off company from The University of Hong Kong, is making waves in the realm of endoscopic surgery with its flexible robotic arms.

Cali Biosciences Co., Ltd. announced it has initiated Phase III studies of its core product, CPL-01, with dosing in hernia patients already begun and dosing in bunion patients scheduled to start next month.

Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage biotech company focused on the development of endogenous regenerative medicines.

At the HIMSS conference in Chicago on Tuesday, pharmacists argued that state and federal regulators should allow them to do more to practice the full scope of their licenses.

Shareholders are being asked to approve a proposal requiring the hospital operator to lay out its policies regarding emergency abortions, and to clarify its statement that it will follow “faith-based commitments.”

The acquisition of Bellus Health will give GSK access to camlipixant, a potentially best-in-class P2X3 antagonist for chronic cough.

Brian Kane, who previously worked as a consultant and was CFO at Humana, will replace Daniel Finke, who is stepping down.